Boston Therapeutics (OTC BB:BTHE)

MANCHESTER, NH--(Marketwire - Nov 14, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, today announced that Jonathan B. Rome, the Company's newly appointed Chief Operating Officer, and the Company entered into a securities purchase agreement pursuant to which Mr. Rome invested $625,000 in the Company's S-1 financial offering to purchase an aggregate of 1,250,000 shares of the Company's common stock at $0.50 per share and 625,000 warrants to purchase 625,000 shares of its common stock. The exercise price of the warrants is $1.00 per share. The warrants have a five-year term. 

MANCHESTER, NH--(Marketwire - Apr 18, 2012) - Boston Therapeutics, Inc. (OTCBB: BTHE), a developer of diabetes therapeutics, today announced that it has received its first commercial purchase order for $157,000 from Advance Pharmaceutical Trading Co., a privately-held company based in Hong Kong.

Boston Therapeutics will manufacture and supply product for Advance Pharmaceutical Trading Co. Advance Pharmaceutical will be responsible for the packaging, marketing and distribution of SUGARDOWN® in the region. Advance Pharmaceutical made an equity investment in Boston Therapeutics to support clinical trials on SUGARDOWN® which concluded last year at University of Sydney in Australia.

"This purchase order is an important milestone in our Asia business development initiative. We believe that Advance Pharmaceutical Trading Co. is an excellent business partner to commercialize SUGARDOWN® in Hong Kong," said Ken Tassey, President of Boston Therapeutics. "Advance Pharmaceutical has a strong market presence in Hong Kong and Southern China with several of its drugs taking lead positions in those markets. We believe Advance's decades of experience in product development, regulatory, licensing, marketing, distribution and international trade provide valuable growth opportunities for Boston Therapeutics," said Tassey.

"We are pleased to make our first product order with Boston Therapeutics to commercialize SUGARDOWN® in China," said Chan Hong Wang Alvin, Marketing Director at Advance Pharmaceutical Trading Co. "SUGARDOWN® has the potential to have a positive impact on the lives of millions of diabetics and pre-diabetics in China. The clinical data from the study at University of Sydney will support our marketing efforts in Hong Kong and China. We value our relationship with Boston Therapeutics and the opportunity to commercialize SUGARDOWN®," said Mr. Chan.

According to an article published in the New England Journal of Medicine, 92 million adults in China have diabetes and 148 million adults are pre-diabetic (Yang, et al., NEJM 2010; 362:1090.).